Partial-brain radiotherapy for primary central nervous system lymphoma: Multi-institutional experience

15Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Whole-brain radiotherapy (WBRT) has been an important component of treatment for primary central nervous system lymphoma (PCNSL), but delayed neurotoxicity has been a matter of concern. We have employed partial-brain radiotherapy (PBRT) with wide margins for PCNSL patients with a single lesion or a few lesions. In this study, we evaluated the treatment outcome in PCNSL patients undergoing PBRT. Between 2003 and 2014, 24 patients were treated with PBRT; 16 received high-dose-methotrexate (MTX) -containing chemotherapy before PBRT. Conventional fractionation with a median dose of 54 Gy was used. For reference, 15 patients undergoing MTX-based chemotherapy and WBRT were also analyzed. The 3-year overall survival rate was 60% for all 24 patients undergoing PBRT and 68% for the 16 patients undergoing MTX-based chemotherapy plus PBRT. The 3-year progression-free survival rate was 41% for all 24 patients undergoing PBRT and 36% for the 16 patients undergoing MTX-based chemotherapy. The in-field recurrence rate was 26% and the out-of-field recurrence rate was 15% at 3 years for all 24 patients undergoing PBRT. The rates for in-field recurrence and the out-of-field recurrence were 27% and 21%, respectively, for the 16 patients undergoing MTX-based chemotherapy. CNS-recurrence rates were similar in patients undergoing MTX-based chemotherapy and PBRT to the rates in those undergoing MTX-based chemotherapy and WBRT. Neurocognitive dysfunction developed in 3 of the 16 patients undergoing MTX + PBRT and in 4 of 15 patients undergoing MTX + WBRT (P = 0.68). PBRT seems to be a feasible treatment option for solitary PCNSL. Further investigations are warranted to evaluate the advantages of PBRT over WBRT.

References Powered by Scopus

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10

636Citations
N/AReaders
Get full text

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome

377Citations
N/AReaders
Get full text

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the European Association for Neuro-Oncology

330Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Primary central nervous system lymphoma: essential points in diagnosis and management

21Citations
N/AReaders
Get full text

Advances and challenges in the treatment of primary central nervous system lymphoma

17Citations
N/AReaders
Get full text

Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Iwabuchi, M., Shibamoto, Y., Sugie, C., Ayakawa, S., Ogino, H., & Baba, F. (2016). Partial-brain radiotherapy for primary central nervous system lymphoma: Multi-institutional experience. Journal of Radiation Research, 57(2), 164–168. https://doi.org/10.1093/jrr/rrv085

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

61%

Researcher 4

22%

Lecturer / Post doc 2

11%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

76%

Nursing and Health Professions 4

19%

Neuroscience 1

5%

Save time finding and organizing research with Mendeley

Sign up for free